Page last updated: 2024-10-24

celiprolol and Obesity

celiprolol has been researched along with Obesity in 4 studies

Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Metoprolol was without significant effect on any of these variables following chronic administration."5.30The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. ( Dietze, GJ; Fogt, DL; Henriksen, EJ; Jacob, S, 1999)
"Celiprolol did not activate lipolysis in rat adipocytes in vitro or stimulate human beta(3)-adrenoceptors expressed in Chinese hamster ovary cells as measured with Cytosensor microphysiometer."1.31Effects of chronic celiprolol treatment on brown fat, feeding, and drinking in fa/fa Zucker rats. ( Huupponen, R; Koulu, M; Luukkaa, V; Malminiemi, K; Pesonen, U; Rouru, J; Savontaus, E, 2000)
"Metoprolol was without significant effect on any of these variables following chronic administration."1.30The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. ( Dietze, GJ; Fogt, DL; Henriksen, EJ; Jacob, S, 1999)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jacob, S1
Fogt, DL1
Dietze, GJ1
Henriksen, EJ1
Malminiemi, K2
Savontaus, E1
Rouru, J1
Luukkaa, V1
Pesonen, U1
Koulu, M1
Huupponen, R1
Taylor, SH1

Trials

1 trial available for celiprolol and Obesity

ArticleYear
Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group.
    Cardiovascular drugs and therapy, 2000, Volume: 14, Issue:1

    Topics: Adrenergic beta-Antagonists; Celiprolol; Fasting; Female; Glucose Tolerance Test; Humans; Hyperlipid

2000

Other Studies

3 other studies available for celiprolol and Obesity

ArticleYear
The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats.
    Life sciences, 1999, Volume: 64, Issue:22

    Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Biological Transport, Active; Blood G

1999
Effects of chronic celiprolol treatment on brown fat, feeding, and drinking in fa/fa Zucker rats.
    Pharmacology, biochemistry, and behavior, 2000, Volume: 65, Issue:4

    Topics: Adipose Tissue, Brown; Adrenergic beta-Antagonists; Animals; Blood Glucose; Body Temperature Regulat

2000
Efficacy of celiprolol in the elderly hypertensive patient.
    American heart journal, 1991, Volume: 121, Issue:3 Pt 2

    Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Cause of Death; Celiprolol; Glucose; Humans; Hype

1991